Onycholysis

    La Roche-Posay
  • May 2022
  • 10min

Therapeutic classes inducing this adverse event
Chemotherapy, EGFR inhibitor, MEK inhibitor, mTOR inhibitor

Onycholysis
Separation of the nail plate, often distal, sometimes responsible of nail loss
Separation of the nail plate, often distal, sometimes responsible of nail loss

CTCAE V5.0

Asymptomatic separation of the nail bed from the nail plate or nail loss

SIMPLIFIED GRADING

Asymptomatic


References


Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Symptomatic separation of the nail bed from the nail plate or nail loss; limiting instrumental ADL

SIMPLIFIED GRADING

Symptomatic OR Limiting instrumental ADL


References


Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

Browse for more adverse events